RBC boosted the price target for Cidara Therapeutics to $75.
1 report, 0 independent
Updated Jun 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
RBC boosted the price target for Cidara Therapeutics to $75.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cidara Therapeutics
company in San Diego, United States
Nothing else this week.
-
Royal Bank of Canada
financial institution in Canada
Related events
- Royal Bank of Canada lifted its target price for Aurinia Pharmaceuticals Inc. on October 9, 2026.
- Royal Bank of Canada raised its price target on Webster Financial on July 2, 2025.
- RBC and Citigroup issued rating and price target updates for Grupo Cibest, with MarketBeat reporting the average rating.
- Royal Bank of Canada reduced its target price for Tenet Healthcare.
- RBC, Keefe, Bruyette & Woods, and Morgan Stanley issued rating and price target updates for D.R. Horton, Inc.
Coverage
Newest first; wire copies grouped- Unknown outlet